🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).
Twittorial below
Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...
1/n
🚀 10-year #FASTForward results confirm that 1-week breast radiotherapy (26 Gy/5 fractions) is safe, effective, and non-inferior to the traditional 3-week RT
✅ Lower local recurrence
✅ Acceptable late toxicity
🔗 https://t.co/5pu2bpSdqs
Long-term oncological outcomes of extended vs limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk #ProstateCancer: Phase 3 randomized controlled trial. Presentation by Jean Felipe Lestingi, MD @Icesp_. #AUA26 written coverage by @zklaassen_md@GACancerCenter > https://t.co/iEBPNH8Tnq @AmerUrological #AUA2026
TDXd now @US_FDA ✅ in neoadjuvant and adjuvant high risk residual HER2+ breast cancer based off DESTINYBreast05 and DESTINYBreast11:
- ⬆️ pCR & iDFS w/ TDXd
- Timings of RT did NOT impact the incidence or severity of ILD
- New Soc for high risk disease!
#bcsm#OncTwitter
My @ASTRO_org 2026 GU spring refresher extended "long-course" slide deck is available at
https://t.co/HND3LmzgZb
You can also watch the "short-course" 1.5 hour narrated version here:
https://t.co/GpDtfapF4K
2026 Genitourinary Oncology Spring Refresher - Dry Run
Updates in the management of cancers of the prostate, bladder, kidney, testes, from @NCCN@ASTRO_org@ESTRO_RT@Uroweb#Radonc residents @ARRO_org, I hope it helps you ace the board exams!
https://t.co/5X8nP1NX0j
Our “Best of” #ESTRO26 outline is now live! 🚀
What key studies are we missing?
Drop any important trials, abstracts, or presentations we should add 👇
https://t.co/MyeQVhxxSk
#RadOnc#ESTRO26#ESTRO2026
1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes".
Paper (open access): https://t.co/EujZFqU7wi
📌Validation of IBS-GEC ESTRO-ABS CT Based Contouring Recommendations using Pre-Brachytherapy MRI in Cancer Cervix Patients Treated with Definitive Radiotherapy
🔗 https://t.co/dZodPchjsh @ASTRO_org@HBCHRC_Punjab@DrShinghal@TMC_Varanasi
👉🏻 One of the largest series that compared CT and MR-based contouring using hybrid-interstitial applications in all patients for validating IBS-GEC ESTRO-ABS guidelines in MRDG – PreBTMR and CTBT environment.
👉🏻 CT based contouring using IBS-GEC ESTRO-ABS recommendations with MRI at diagnosis and brachytherapy, is safe, convenient and addresses logistic issues in institutions, especially LMICs.
Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc@DanaFarberNews@jdschoenfeld1
https://t.co/53tHQtj8pl
TROPION-Breast02:
Dato-DXd redefines 1L mTNBC beyond efficacy alone.
A near 3-fold prolongation in QoL preservation vs chemotherapy (TTD 23.5 vs 8.3 mo; HR 0.64) signals a paradigm shift toward "quality survival"
#ESMOBreast26@OncoAlert#mTNBC#ADCs#bcsm
#ESMOBreast26
Treatment Optimization in early HR+/HER2− BC
Low-risk: ET
High-risk: chemo + ET + CDK4/6i
The unresolved question is the intermediate-risk group:
There is no definitive answer yet, but for now, decisions can be guided by indirect evidence and individualized risk assessment
Simultaneous publication with #ESMOBreast26
An excellent de-escalation study: PHERGain-2 study
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer
https://t.co/3XmXpbc7UN